Understanding severe reactions to blood transfusions in sickle cell disease
Transfusion-driven hyperhemolysis in sickle cell disease
['FUNDING_R01'] · NEW YORK BLOOD CENTER · NIH-10904817
This study is looking at how blood transfusions can sometimes cause serious problems for people with sickle cell disease, especially a reaction where both the new and old blood cells can be harmed, and it aims to find out why this happens so we can better prevent and treat these issues.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK BLOOD CENTER (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10904817 on ClinicalTrials.gov |
What this research studies
This research investigates the severe complications that can arise from blood transfusions in patients with sickle cell disease, specifically focusing on delayed hemolytic transfusion reactions (DHTR). The study aims to uncover the mechanisms that lead to these unpredictable and potentially life-threatening reactions, where both transfused and the patient's own red blood cells are destroyed. By examining the role of type I interferon and its effects on immune cells, the research seeks to improve prevention and treatment strategies for these complications. Patients may be monitored for their response to transfusions and the associated immune reactions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 21 and older with sickle cell disease who require blood transfusions.
Not a fit: Patients who do not have sickle cell disease or those who do not require blood transfusions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better management and treatment options for patients experiencing severe transfusion reactions, ultimately improving their quality of life.
How similar studies have performed: Previous research has indicated that understanding immune responses in transfusion reactions can lead to improved treatment protocols, suggesting that this approach has potential for success.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK BLOOD CENTER — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AN, XIULI — NEW YORK BLOOD CENTER
- Study coordinator: AN, XIULI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.